ClinicaliQ Trial Snapshot
- A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias — Recruiting • Phase I • Cardiology / Cardiovascular • NCT07491172.
- Drug being tested: CTX310 is undergoing Phase 1 evaluation in a single-arm, open-label design with ascending doses to establish safety and tolerability in adults aged 18-75 years with treatment-refractory dyslipidaemia.
- Patient population: Eligible participants have dyslipidaemias that have not responded adequately to conventional lipid-lowering therapies, representing a clinically challenging group with limited therapeutic options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Eligibility Snapshot
- Key Inclusion Criteria: 1. Age of ≥18 and ≤75 years at the time of signing the informed consent. 2. Able to provide written informed consent.
- Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg/dL - and LDL-C ≥70 mg/dL in participants with ASCVD, or LDL-C ≥70 or 100mg/dL in participants with or without ASCVD respectively, or TG ≥500 mg/dL. 4. Refractory to the maximal intensity or MTD of standard of care lines of lipid-lowering therapies available through routine clinical care, for at least 12 weeks prior to screening 5. Female participants must be postmenopausal or surgically sterile. 6. All male participants and their female partners must agree to the use of an acceptable method of effective contraception for the duration of the study.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.